Related Experiment Videos
Pirbuterol, a selecttve beta2 adrenergic bronchodilator
The Journal of Pharmacology and Experimental Therapeutics
|November 1, 1978
Summary
Pirbuterol is a novel beta2 adrenergic agonist bronchodilator with superior selectivity for pulmonary tissue compared to cardiac tissue. This makes it a promising therapeutic agent for respiratory conditions.
Area of Science:
- Pharmacology
- Respiratory Medicine
Background:
- Pirbuterol is a novel beta2 adrenergic agonist.
- Beta2 adrenergic agonists are commonly used as bronchodilators.
Purpose of the Study:
- To evaluate the relative potency and selectivity of pirbuterol.
- To compare pirbuterol with salbutamol and isoproterenol.
Main Methods:
- In vitro studies using guinea-pig tracheal muscle and atria.
- In vivo studies in conscious and anesthetized guinea pigs and dogs.
Main Results:
- Pirbuterol demonstrated significantly greater selectivity for pulmonary versus cardiac tissue than salbutamol and isoproterenol.
- Pirbuterol effectively antagonized bronchoconstriction and anaphylaxis in guinea pigs.
- Pirbuterol showed distinct cardiovascular effects compared to salbutamol in dogs.
Conclusions:
- Pirbuterol is a highly selective beta2 adrenergic agonist bronchodilator.
- Its selectivity profile suggests a potentially improved therapeutic index for respiratory diseases.
- Pirbuterol offers effective bronchodilation via multiple routes of administration.